文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于整合医学的东亚草药治疗类风湿关节炎炎症性疼痛：系统评价和荟萃分析与多数据挖掘相结合的核心候选药物发现方案。

Integrative medicine using East Asian herbal medicine for inflammatory pain in patients with rheumatoid arthritis: A protocol for systematic review and meta-analysis integrated with multiple data mining for core candidate discovery.

机构信息

Department of Herbal Pharmacology, College of Korean Medicine, Gachon University, Seongnam, Republic of Korea.

Naturalis Inc., Seongnam, Republic of Korea.

出版信息

Medicine (Baltimore). 2023 Jun 9;102(23):e33903. doi: 10.1097/MD.0000000000033903.

DOI:10.1097/MD.0000000000033903
PMID:37335629
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10256327/
Abstract

BACKGROUND: Rheumatoid arthritis is a chronic inflammatory autoimmune disease characterized by a wide range of clinical symptoms affecting various bodily functions, including skeletal, vascular, metabolic, and cognitive functions. This review aimed to evaluate the efficacy and safety of integrative medicine (East Asian herbal medicine combined with conventional medicine) used for the treatment of inflammatory pain in rheumatoid arthritis and to identify key candidate drugs based on the data. METHODS: A comprehensive literature search will be conducted in 4 core databases (PubMed, Excerpta Medica database, Cochrane Library, and Cumulative Index to Nursing & Allied Health Literature) 4 Korean databases (Oriental Medicine Advanced Searching Integrated System, Korean Studies Information Service System, Research Information Service System, and Korea Citation Index), 2 Chinese databases (Chinese National Knowledge Infrastructure Database and Wanfang data), and 1 Japanese database (Citation Information by National Institute of Informatics) for randomized controlled trials from December 13, 2022. Statistical analysis will be performed using R version 4.1.2 and R Studio program. The American College of Rheumatology 20/50/70 score and rate of adverse events will be the primary outcomes. All outcomes will be analyzed using a random-effects model to produce more statistically conservative results. Sensitivity, meta-regression, and subgroup analyses will be used to identify the sources of any heterogeneity in the study. The revised tool for assessing the risk of bias in randomized trials, version 2.0, will be used to evaluate methodological quality. The overall quality of evidence will be assessed according to the Grading of Recommendations Assessment, Development, and Evaluation Pro Framework. ETHICS AND DISSEMINATION: There are no ethical issues, as no primary data will be collected directly from the participants. The results of this review will be reported in a peer-reviewed scientific journal. TRIAL REGISTRATION: PROSPERO registration number: CRD42023412385.

摘要

背景：类风湿关节炎是一种慢性炎症性自身免疫性疾病，其临床症状广泛，影响多种身体功能，包括骨骼、血管、代谢和认知功能。本综述旨在评估东亚草药联合常规药物治疗类风湿关节炎炎症性疼痛的疗效和安全性，并根据数据确定关键候选药物。

方法：我们将对 4 个核心数据库（PubMed、Excerpta Medica 数据库、Cochrane 图书馆和 Cumulative Index to Nursing & Allied Health Literature）、4 个韩国数据库（Oriental Medicine Advanced Searching Integrated System、Korean Studies Information Service System、Research Information Service System 和 Korea Citation Index）、2 个中国数据库（中国国家知识基础设施数据库和万方数据）和 1 个日本数据库（国立情报学研究所的引文信息）进行全面的文献检索，以查找 2022 年 12 月 13 日以后发表的随机对照试验。使用 R 版本 4.1.2 和 R Studio 程序进行统计分析。美国风湿病学会 20/50/70 评分和不良事件发生率将作为主要结局。所有结局都将使用随机效应模型进行分析，以产生更具统计学稳健性的结果。敏感性分析、Meta 回归和亚组分析将用于确定研究中任何异质性的来源。将使用修订版随机试验偏倚风险评估工具（version 2.0）评估方法学质量。根据 Grading of Recommendations Assessment, Development, and Evaluation Pro 框架，评估证据的总体质量。

伦理和传播：由于不会直接从参与者那里收集原始数据，因此不存在伦理问题。本综述的结果将在同行评议的科学期刊上报告。

试验注册：PROSPERO 注册号：CRD42023412385。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a394/10256327/24fdd559d742/medi-102-e33903-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a394/10256327/24fdd559d742/medi-102-e33903-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a394/10256327/24fdd559d742/medi-102-e33903-g001.jpg

相似文献

[1]
Integrative medicine using East Asian herbal medicine for inflammatory pain in patients with rheumatoid arthritis: A protocol for systematic review and meta-analysis integrated with multiple data mining for core candidate discovery.

Medicine (Baltimore). 2023-6-9

[2]
Oral administration of East Asian herbal medicine for rheumatoid arthritis: A protocol for systematic review and meta-analysis.

Medicine (Baltimore). 2022-2-11

[3]
Integrative medicine (East Asian herbal medicine combined with conventional medicine) for psoriasis: A protocol for systematic review and meta-analysis.

Medicine (Baltimore). 2023-1-20

[4]
East Asian herbal medicine for cancer pain: A protocol for systematic review and meta-analysis with using association rule analysis to identify core herb pattern.

Medicine (Baltimore). 2021-11-12

[5]
Herbal medicine on cancer-related fatigue of lung cancer survivors: Protocol for a systematic review.

Medicine (Baltimore). 2020-1

[6]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[7]
East Asian Herbal Medicine to Reduce Primary Pain and Adverse Events in Cancer Patients : A Systematic Review and Meta-Analysis With Association Rule Mining to Identify Core Herb Combination.

Front Pharmacol. 2022-1-17

[8]
East asian herbal medicine for the treatment of children with attention deficit hyperactivity disorder: A Systematic Review and Meta-analysis.

Explore (NY). 2023

[9]
Herbal medicine (Hyeolbuchukeo-tang or Xuefu Zhuyu decoction) for treating primary dysmenorrhoea: protocol for a systematic review of randomised controlled trials.

BMJ Open. 2017-6-15

[10]
Herbal medicine Banha-sasim-tang for the treatment of functional dyspepsia protocol for a systematic review of randomized controlled trials.

Medicine (Baltimore). 2019-5

本文引用的文献

[1]
The pathogenesis of rheumatoid arthritis.

Immunity. 2022-12-13

[2]
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.

Ann Rheum Dis. 2023-1

[3]
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.

Ann Rheum Dis. 2023-1

[4]
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.

Ann Rheum Dis. 2023-1

[5]
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.

Ann Rheum Dis. 2023-1

[6]
Inflammation mediates approximately one quarter of excess relative all-cause mortality in persons with rheumatoid arthritis: the Trøndelag Health Study.

Sci Rep. 2022-11-3

[7]
The combination of Chinese and Western Medicine in the management of rheumatoid arthritis: A real-world cohort study across China.

Front Pharmacol. 2022-10-6

[8]
Clinical evidence construction of East Asian herbal medicine for inflammatory pain in rheumatoid arthritis based on integrative data mining approach.

Pharmacol Res. 2022-11

[9]
Conventional disease-modifying anti-rheumatic drugs combined with Chinese Herbal Medicines for rheumatoid arthritis: A systematic review and meta-analysis.

J Tradit Complement Med. 2022-1-26

[10]
Global epidemiology of rheumatoid arthritis.

Nat Rev Rheumatol. 2022-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索